Combination therapy for advanced breast cancer resistant to CDK4/6 inhibitors
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests two treatments for advanced breast cancer that has stopped responding to a common class of drugs. It combines a targeted pill (famitinib) with an experimental antibody-drug treatment (SHR-A1811) to see if the combination works better than the antibody-drug alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- You must have a type of breast cancer called hormone receptor-positive (HR+) and HER2-negative, with low or very low HER2 levels.
- Your cancer must be locally advanced (cannot be removed by surgery) or have spread to other parts of the body.
- You must have already tried a type of drug called a CDK4/6 inhibitor (like palbociclib, ribociclib, or abemaciclib), or your cancer came back within a year of finishing one.
- You will need to have at least one tumor that can be measured on a CT scan, or if not, you need bone lesions that are visible on imaging.
- Your overall health must be reasonably good, with adequate blood counts, kidney and liver function, and no major heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
This trial tests a new drug (SHR-A1811) combined with fulvestrant, with or without another drug (HS-10352), for people with advanced breast cancer that has not been treated before. The goal is to see if these combinations can help control the cancer.
This trial is testing a combination of two targeted therapies for a specific type of triple-negative breast cancer. The goal is to see if adding a second drug improves the effectiveness of the first treatment in slowing the cancer's growth.
This study tests a new drug (SHR-1811) combined with a standard chemotherapy drug (carboplatin) for advanced breast cancer that shows HER2, even at low levels. It may offer a new option for people whose cancer has stopped responding to previous treatments.
This study tests whether adding a drug called everolimus to a targeted therapy called trastuzumab rezetecan is more effective than the targeted therapy alone for people with a specific type of triple-negative breast cancer (called LAR subtype) that has spread or come back. The combination aims to improve treatment response and potentially help you live longer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.